OTTAWA--The issue of Intellectual Property Rights (IPRs) for pharmaceuticals has returned to the agenda partly as a result of the Romanow Report but also because drug companies are pushing for extended patent protection. In the wake of the current House of Commons Industry, Science and Technology committee hearings, a new CCPA study by Dr. Joel Lexchin--"Intellectual Property Rights and the...
Issue(s): Health, Health care system, Pharmacare
June 9, 2003
Printed copies of this article can be purchased from the National Office for: $10
Download Now
162 KB PDF | 26 pages
162 KB PDF | 26 pages
Over the last 30 years, the CCPA has provided alternative research and analysis that have been indispensable in exposing the corporate agenda. I don’t know what I’d have done without them.